HEALTH Gene Technologies Co., Ltd. achieved ￥220 million ($32.35 million) A-round financing

Booth No. of 2021 CACLP: N5-T009

Multiple nucleic acid test supplier, HEALTH Gene Technologies Co., Ltd. announced that ￥220 million RMB A-round financing completed on Dec. 1st led by Qiming Weichuang Venture Capital, followed by GL Capital, Biotrack capital, Jingxun Venture Investment and Blue Lake Capital Consulting. The fund of the investment will focus on new product development, capacity enlarging and market expansion.

HEALTH Gene (HGT) established in Aug. 2011, focusing on research, manufacturing, marketing and application service for the field of nucleic acid (genetic) analyzing and molecular diagnosis. The company makes the great effort on clinical laboratory and forensic science possessing 3 product series of clinical molecular diagnostic reagent, nucleic acid test analyzer and DNA test reagent for forensic science.

Tens of millions of Angel round financing to Boyue Bio

Booth No. of 2021 CACLP: N1-T034

Hangzhou Boyue Bio-Tech Co., Ltd. completed tens of millions of Angel round financing in recent which was invested by Cowin Venture Capital in exclusive. The fund is for new product development, capacity enlarging and market expansion.

Established on 2018, Boyue Bio-Tech dedicated in core materials and integrated solution for IVD customers. Based on molecular biology, immunology, biochemistry, proteomics and polymer nanomaterials, the company set up the research and producing platform on monoclonal /polyclonal antibody, prokaryotic / eukaryotes protein expression, protein purifying, materials evaluation and nano materials.

Sunlant bioengineering completed the tens of millions of Pre-IPO financing

Booth No. of 2021 CACLP: N7-T022

Reported on No. 25th, Jiangsu Sunlant Bioengineering Co., Ltd. announced that tens of millions of Pre-IPO financing has been completed for the couple of days with 4 investors of Guangzhou Jinyu Equity, Suzhou Xiangcheng Financial Holdings, Tianjin TEDA Venture Capita &, Suzhou Lanhu Equity Investment.

Sunlant bioengineering is the first company in the world to specialise in the application of CLIA, Multi-index parallel detection and full-automatic protein chip analysis technologies for systematic detection serious diseases. Company has the lead position of full-automatic biochip detection platform, 2 research achievements of “863”program, one major industrial project in jiangsu province and more than 30 patents. The output of the very first fully automated analytical system for the protein biochip has filled the gap in the multi-index detection field . The product has covered many AAA hospitals and health check-up institutions, breaking the long-term foreign product monopoly and technology blockade in the field of high technological detection. Sunlant Bioengineering is providing the best clinical detection based on our professional teams of research, produce, sales and aftersales.

Huiyan Bio completed the tens of millions of A-round financing

Booth No. of 2021 CACLP: N4-B651

Working on domestic protein purifying technology, Wu Han Huiyan Bio Tech Co., Ltd. announced completing tens of millions of A-round financing recently. It invested by Shanghai Greenriver Investment in exclusive which is used for the Agarose Beads establishment of product line with 10000L for satisfying the rapid demand of domestic proteins separation purifying packing.

Established on 2013, Huiyan Bio devoted itself on researching, manufacturing, marketing for bio-separation purifying medium and is the rare company whom mastered the core prilling technology of Agarose Beads with over 100 kinds of proteins separation purifying packing on 4 major categories product line embracing molecular sieve, ion exchange, affinity and hydrophobic. The 1000L microsphere reactor has constantly producing 4 years applying on several product line of bio manufacturers realizing the domestic substitutability.